CompletedNCT03720847
Ovarian Hormone Supplementation and Suicidal Symptoms Around the Menstrual Cycle
About this title
Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality
Read the official source — NCT03720847Medication studyAges 18–45United StatesSuicide prevention
Understand this study
Who was this study for?
Listed age limits: 18 years to 45 years.
- Listed locations
- Chapel HillSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: December 31, 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 30
- Sponsor
- University of North Carolina, Chapel Hill
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT03720847
- Official title
Show the full official title
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Chapel Hill
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of North Carolina, Chapel Hill, a university.
Did this study involve medication?
Yes. The study involved medication, including Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone, Inactive Clear Patch and Placebo capsule.
Who was this study for?
Listed age limits: 18 years to 45 years.
